Your browser doesn't support javascript.
loading
Successful serial plasmapheresis for solar urticaria, a case report and literature review.
Boontaveeyuwat, Einapak; Willis, Fenella; Fassihi, Hiva; Sarkany, Robert P E.
Afiliação
  • Boontaveeyuwat E; Photodermatology Unit, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Willis F; Photodermatology Unit, Division of Dermatology, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Fassihi H; Haematology Department, St. George's University Hospitals NHS Foundation Trust, London, UK.
  • Sarkany RPE; Photodermatology Unit, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
J Dermatolog Treat ; 35(1): 2350229, 2024 Dec.
Article em En | MEDLINE | ID: mdl-38880493
ABSTRACT
BACKGROUND/

PURPOSE:

Amidst the emergence of new therapeutic options, traditional therapeutic plasmapheresis (TPE) used in diseases involving a toxic substance in the plasma, remains a viable alternative for cases of recalcitrant solar urticaria (SU). We emphasize the importance of documenting successful experience with repeated plasmapheresis to increase awareness amongst physicians and dermatologists regarding this effective treatment option. MATERIAL AND

METHOD:

We reported a case of recalcitrant SU that had not responded to a combination of H1-antihistamines, immunosuppressants, omalizumab and intravenous immunoglobulin. We introduced serial TPE, which involved two consecutive days of procedures for each course was introduced. We detailed the regimen and highlighted the clinical and objective benefits observed with multiple treatments. Additionally, we compared this to other plasmapheresis regimens and their treatment responses previously reported for solar urticaria.

RESULTS:

Our patient underwent serial TPE, totaling 42 procedures over five years. Following the last TPE session, phototesting showed a sustained prolongation of minimal urticating doses (MUDS), which exceeded the maximum tested doses across nearly all ultraviolet (UV) and visible light ranges, with the exception of the two short ultraviolet B (UVB) wavelengths. MUDs increased to 25 from 6 mj/cm2 at 307.5± 5nm, and to 500 from 15 mj/cm2 at 320 ± 10nm, before the initial TPE. In our review, we included five articles covering eight SU patients who received TPE. Of these, the five patients with positive intradermal tests responded particularly well immediately after treatment. However, the condition relapsed within two weeks in one patient and within two months in another. In contrast, the other three patients with negative intradermal tests, showed no significant benefits from the treatment. No serious side effects from TPE were reported amongst the patients.

CONCLUSIONS:

This review underscores the efficacy of serial plasmapheresis procedures in treating refractory cases of SU, high3lighting the robust results observed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Urticária / Plasmaferese Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Urticária / Plasmaferese Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article